Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Alisa Damnernsawad"'
Autor:
Xiaona You, Myung-Jeom Ryu, Eunjin Cho, Yanzhi Sang, Alisa Damnernsawad, Yun Zhou, Yangang Liu, Jing Zhang, Youngsook Lee
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Ras proteins control a complex intracellular signaling network. Gain-of-function mutations in RAS genes lead to RASopathy disorders in humans, including Noonan syndrome (NS). NS is the second most common syndromic cause of congenital heart disease. A
Externí odkaz:
https://doaj.org/article/61616fac3a9d456fa2f6b16adf00e978
Autor:
Alisa Damnernsawad, Daniel Bottomly, Stephen E. Kurtz, Christopher A. Eide, Shannon K. McWeeney, Jeffrey W. Tyner, Tamilla Nechiporuk
Publikováno v:
Haematologica, Vol 107, Iss 1 (2020)
Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatmen
Externí odkaz:
https://doaj.org/article/77ae0d83a6244d158ead1609052ab16a
Autor:
Su Lin Lim, Alisa Damnernsawad, Pavithra Shyamsunder, Wee Joo Chng, Bing Chen Han, Liang Xu, Jian Pan, Dakle Pushkar Pravin, Serhan Alkan, Jeffrey W. Tyner, H. Phillip Koeffler
Publikováno v:
Haematologica, Vol 104, Iss 6 (2019)
Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of vario
Externí odkaz:
https://doaj.org/article/9021855a10e84e4687b818197b0e2f3b
Autor:
Sara J. C. Gosline, Cristina Tognon, Michael Nestor, Sunil Joshi, Rucha Modak, Alisa Damnernsawad, Camilo Posso, Jamie Moon, Joshua R. Hansen, Chelsea Hutchinson-Bunch, James C. Pino, Marina A. Gritsenko, Karl K. Weitz, Elie Traer, Jeffrey Tyner, Brian Druker, Anupriya Agarwal, Paul Piehowski, Jason E. McDermott, Karin Rodland
Publikováno v:
Clinical Proteomics. 19
Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populati
Autor:
Christopher A. Eide, Stephen E. Kurtz, Shannon K. McWeeney, Tamilla Nechiporuk, Daniel Bottomly, Alisa Damnernsawad, Jeffrey W. Tyner
Publikováno v:
Haematologica. 107:77-85
Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatmen
Kras-Deficient T Cells Attenuate Graft-versus-Host Disease but Retain Graft-versus-Leukemia Activity
Autor:
Alisa Damnernsawad, Juan C. Felix, Yuhong Chen, Renren Wen, Chunji Gao, Guoping Fu, Robert Burns, Christopher P. Hartley, Demin Wang, Yongwei Zheng, Jing Zhang, Lan Luo, Mei Yu, Xiao Chen, Wen Zhu, Vivian Zhou, Williams R Drobyski
Publikováno v:
J Immunol
Acute graft-versus-host disease (aGVHD) is one major serious complication that is induced by alloreactive donor T cells recognizing host Ags and limits the success of allogeneic hematopoietic stem cell transplantation. In the current studies, we iden
Proteomics and Phosphoprotoemic Measurements Enhance Ability to Predict Ex Vivo Drug Response in AML
Autor:
Sara Gosline, Cristina Tognon, Michael Nestor, Sunil Joshi, Rucha Modak, Alisa Damnernsawad, Camilo Posso, Jamie Moon, Joshua R. Hansen, Chelsea Hutchinson-Bunch, James C Pino, Marina A. Gritsenko, Karl K. Weitz, Elie Traer, Jeffrey Tyner, Brian Druker, Anupriya Agarwal, Paul Piehowski, Jason E. McDermott, Karin Rodland
Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::690033e2a94538c9a72d87549e971271
https://doi.org/10.21203/rs.3.rs-1277906/v1
https://doi.org/10.21203/rs.3.rs-1277906/v1
Autor:
Quinlan Morrow, David A. Sampson, James L. Zehnder, Talent Theparee, Jason Gotlib, William Shomali, Richard D. Press, Alisa Damnernsawad, Fei Yang, Sebastian Fernandez-Pol, Jeffrey W. Tyner
Publikováno v:
Blood Adv
Hypereosinophilia (HE) has been defined as persistent eosinophilia >1.5 × 109/L; it is broadly divided into primary HE (clonal or neoplastic; HEN), secondary/reactive HE (HER), or HE of undetermined significance (HEUS) when no cause is identified. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::513bbf11dc55093accf54b603e97007f
https://europepmc.org/articles/PMC8945578/
https://europepmc.org/articles/PMC8945578/
Autor:
Karl K. Weitz, Hutchinson-Bunch C, Rucha V. Modak, Sunil K. Joshi, Marina A. Gritsenko, Cristina E. Tognon, Drucker B, Anupriya Agarwal, Paul D. Piehowski, Karin D. Rodland, Jamie Moon, Hansen, Alisa Damnernsawad, Elie Traer, Sara J Gosline, Jason E. McDermott, Nestor M
Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31f0195ca82f2684b9e1e06b2576b3ad
https://doi.org/10.1101/2021.06.04.447154
https://doi.org/10.1101/2021.06.04.447154
Autor:
Alisa Damnernsawad, Wee Joo Chng, Jian Pan, Jeffrey W. Tyner, Su Lin Lim, Pavithra Shyamsunder, H. Phillip Koeffler, Serhan Alkan, Liang Xu, Bingchen Han, Dakle Pushkar Pravin
Publikováno v:
Haematologica
Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of vario